Chemcd News List Press Releases from Chemcd News List Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence. Fri, 29 Jan 2016 07:40:32 GMT chemcd 2016-01-29T07:40:32Z Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab. Mon, 11 Jan 2016 07:16:55 GMT chemcd 2016-01-11T07:16:55Z First data backs efficacy of BMS' novel HIV drug A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study. Fri, 30 Oct 2015 09:46:29 GMT chemcd 2015-10-30T09:46:29Z EU Rules Could Restrict Genetic Testing Genetic testing describes the application of laboratory methods to look at a person&#8217;s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments. Fri, 30 Oct 2015 03:21:20 GMT chemcd 2015-10-30T03:21:20Z CHMP adopts positive opinion of Edurant in adolescents with HIV-1 The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection Tue, 27 Oct 2015 08:38:21 GMT chemcd 2015-10-27T08:38:21Z FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset. Tue, 20 Oct 2015 07:52:18 GMT chemcd 2015-10-20T07:52:18Z Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology. Tue, 20 Oct 2015 07:46:42 GMT chemcd 2015-10-20T07:46:42Z FDA OKs Multipathogen Nucleic Acid Test for CNS Infections FDA today approved the first nucleic acid-based test of cerebrospinal fluid (CSF) that can simultaneously detect 14 pathogens responsible for central nervous system (CNS) infections. Fri, 09 Oct 2015 10:17:00 GMT chemcd 2015-10-09T10:17:00Z Stopping Hormone Therapy Linked to Cardiovascular Death Hormone therapy guidelines for postmenopausal women recommend the lowest dose for the briefest period. "This has led to the clinical practice of pulling women off hormone therapy annually or biannually, Fri, 09 Oct 2015 10:11:31 GMT chemcd 2015-10-09T10:11:31Z Otsuka wins early FDA approval for a colorectal cancer combo drug Japanese drugmaker Otsuka won FDA approval for a two-drug therapy for colorectal cancer, planning to market the combination as a treatment for advanced forms of the disease. Wed, 23 Sep 2015 08:15:38 GMT chemcd 2015-09-23T08:15:38Z Celgene's Abraxane takes another hit from cost-effectiveness gatekeepers Celgene's ($CELG) Abraxane can't catch a break in England. Soon after losing coverage for pancreatic cancer on the country's dedicated Cancer Drugs Fund, the treatment got another thumbs-down from its official cost-effectiveness watchdogs. Mon, 21 Sep 2015 02:56:44 GMT chemcd 2015-09-21T02:56:44Z Roche preps for make-or-break MS data with eyes on a crowded space Roche preps for make-or-break MS data with eyes on a crowded space.Roche's in-development treatment for multiple sclerosis met its main efficacy goals in pair of Phase III trials Mon, 21 Sep 2015 02:49:00 GMT chemcd 2015-09-21T02:49:00Z China's State Council unveils triage plan to funnel first patient visits to clinics China has moved to overhaul the way patients seek medical care by attempting to break the habit of heading to a big hospital in a major city and instead encouraging folks to seek local advice and referrals first--all in an effort to get a handle on soaring care costs. Wed, 16 Sep 2015 09:10:00 GMT chemcd 2015-09-16T09:10:00Z MYC/PGC-1‚Î Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells The anti-diabetic drug metformin targets pancreatic cancer stem cells (CSCs), but not their differentiated progenies (non-CSCs), which may be related to distinct metabolic phenotypes. Wed, 16 Sep 2015 09:03:03 GMT chemcd 2015-09-16T09:03:03Z The World's Largest Healthcare Event -- tHIS Opens to Record Breaking Crowds in Shanghai The 2015 Health Industry Summit (tHIS), an event that is predicted to transform the Chinese healthcare industry sector, opened to huge crowds on May 15, with over 210,000 visitors from 150 countries in attendance. Tue, 19 May 2015 09:34:04 GMT chemcd 2015-05-19T09:34:04Z Tekmira Pharmaceuticals is planning to resume its Phase I study of an investigational treatment for Ebola Canadian biotech Tekmira Pharmaceuticals ($TKMR) is planning to resume its Phase I study of an investigational treatment for Ebola now that the FDA has waved off some lingering safety concerns. The agency had effectively halted development of TKM-Ebola, an RNAi therapy Mon, 13 Apr 2015 10:28:57 GMT chemcd 2015-04-13T10:28:57Z Shire PLC (ADR) Eyes BioMarin Pharmaceutical Inc. BioMarin stock has rallied up 5% in extended trading on news that Shire is interested in acquiring the company Word on the Street is that Shire plc Tue, 31 Mar 2015 09:39:25 GMT chemcd 2015-03-31T09:39:25Z Chinese New Year holiday Holiday arrangements for Chinese SpringFestival. 14th February to 24th February(11days), 9th February will be adjusted towork. Fri, 13 Feb 2015 06:50:17 GMT chemcd 2015-02-13T06:50:17Z Novartis faces suspension in Japan after series of trial datas candals Japan plans to temporarily suspend Novartis' ($NVS) pharma business in that countryĺQ?according to media reports. The Ministry of HealthĺQ?Labour and Welfare's order will last about 15 days and will cite repeated violations of failure to report adverse events properlyĺQ?the Japan Timessays. Thu, 05 Feb 2015 07:11:14 GMT chemcd 2015-02-05T07:11:14Z Pfizer strikes another immunotherapy deal to widen its oncology pipeline Pfizer has agreed to pay iTeos Therapeutics â‚?4 million ($30 million) up front for the exclusive rights to some preclinical candidates, also making an undisclosed equity investment in the company and promising untold milestone payments down the line. Wed, 10 Dec 2014 07:43:40 GMT chemcd 2014-12-10T07:43:40Z 国产超碰人人做人人爽AV,在车子颠簸中进了她身体,白洁一夜被爽了七次,老师穿旗袍白丝让我爽翻天av
<var id="brxvh"></var>
<var id="brxvh"></var>
<var id="brxvh"><video id="brxvh"><thead id="brxvh"></thead></video></var>
<cite id="brxvh"><video id="brxvh"><thead id="brxvh"></thead></video></cite><address id="brxvh"><cite id="brxvh"><strike id="brxvh"></strike></cite></address>
<var id="brxvh"></var><var id="brxvh"></var><var id="brxvh"><video id="brxvh"></video></var>
<cite id="brxvh"><span id="brxvh"></span></cite>
<cite id="brxvh"></cite>